...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thyroid: official journal of the American Thyroid Association >The effect of ginkgo biloba extract on genotoxic damage in patients with differentiated thyroid carcinoma receiving thyroid remnant ablation with iodine-131
【24h】

The effect of ginkgo biloba extract on genotoxic damage in patients with differentiated thyroid carcinoma receiving thyroid remnant ablation with iodine-131

机译：银杏叶提取物对分化型甲状腺癌接受碘131消融术对分化型甲状腺癌患者遗传毒性的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Radioiodine ( 131I) therapy is usually performed in patients with differentiated thyroid cancer (DTC). Although 131I is generally considered safe, genotoxic damage has been demonstrated both in vivo and in vitro. The aim of the current study was to evaluate the effect of Ginkgo biloba extract (GBE) on the time-course of appearance, after 131I therapy for DTC, of plasma factors with chromosome-damaging properties (so-called "clastogenic" factors [CFs]) and of micronuclei (MN) in lymphocytes. Methods: Twenty-three patients (median age 42 years, range 18-73) with DTC receiving 131I activity (3.7GBq) for thyroid remnant ablation were randomly assigned to receive GBE (120mg/day for one month; n=10) or placebo (n=13) in a double-blind manner. Blood samples were taken at various intervals (from baseline to 90 days) after 131I therapy. The frequency of MN in blood lymphocytes was determined, and CFs were assayed in plasma by a method that used MN increase in lymphocytes from an healthy donor as the endpoint of the assay. Results: MN in blood lymphocytes increased significantly after 131I treatment in the placebo group, peaking at the 7th day (p=0.002) and slowly declining thereafter. In contrast, in similarly treated patients who were also treated with GBE both before and after 131I treatment, a significant increase of blood lymphocyte MN level was not observed. In addition, only the placebo group showed a significant, progressive increase in CFs activity. This peaked at the 14th day (p=0.003 vs. baseline) and was still noted for the last plasma sample. The differences in the change in lymphocyte MN and CFs activity between the placebo and GBE-treated groups were significant (p0.01 and p0.05, respectively). Thyroid function tests, including serum thyroglobulin (Tg) and anti-Tg antibody levels, were never significantly different. Conclusions: GBE may protect from possible oxidative and genotoxic damage associated with 131I treatment in patients requiring 131I therapy for thyroid cancer, without affecting the clinical outcome. Further studies with larger cohorts of patients are needed to confirm this report and verify the beneficial effect of GBE in patients requiring 131I therapy, particularly for those in whom repeated treatments and high activities of 131I are required.
机译：背景：放射性碘（131I）疗法通常在分化型甲状腺癌（DTC）患者中进行。尽管通常认为131I是安全的，但已在体内和体外证明了遗传毒性损害。本研究的目的是评估银杏叶提取物（GBE）对131I治疗DTC后具有染色体破坏特性的血浆因子（所谓的“致死性”因子[CFs]）出现的时间过程的影响。 ]）和淋巴细胞中的微核（MN）。方法：23例接受131I活性（3.7GBq）甲状腺残留消融的DTC患者（中位年龄42岁，范围18-73）随机分配接受GBE（120mg /天，为期1个月; n = 10）或安慰剂。 （n = 13）以双盲方式显示。 131I治疗后的不同时间间隔（从基线到90天）采集血样。确定血液淋巴细胞中MN的频率，并通过一种方法检测血浆中的CF，该方法使用来自健康供体的淋巴细胞中MN的增加作为测定的终点。结果：安慰剂组在131I治疗后血液淋巴细胞中的MN显着增加，在第7天达到峰值（p = 0.002），此后缓慢下降。相反，在同样接受131I治疗之前和之后也接受GBE治疗的患者中，未观察到血中MN的显着增加。此外，只有安慰剂组的CFs活性显着升高。该浓度在第14天达到峰值（相对于基线，p = 0.003），最后一次血浆样品仍可观察到。安慰剂组和GBE治疗组之间的淋巴细胞MN和CFs活性变化差异显着（分别为p <0.01和p <0.05）。甲状腺功能测试（包括血清甲状腺球蛋白（Tg）和抗Tg抗体水平）从未发生显着差异。结论：对于需要131I治疗的甲状腺癌患者，GBE可以防止与131I治疗相关的氧化和遗传毒性损害，而不会影响临床结果。需要对更大数量的患者进行进一步的研究，以证实该报告并验证GBE在需要131I治疗的患者中的有益作用，尤其是对于那些需要反复治疗和高活性131I的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号